Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Håkon Astrup
  • Jon Berggren
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Weak report across the board

Patrik Ling

Getinge (Buy, TP: SEK150.00) - A little soft on the margin

Getinge’s Q2 report was mixed. Sales and order intake were better than expected but adj. EBITA margin fell short of expectations. The company announced additional cost-saving initiatives in the Surgical Workflows (SW) operation and said some effect from these actions should be visible in H2. We believe the company is executing on its turnaround, but that 2019 is still a transition year and there will be a bumpy road for some time. We reiterate our BUY recommendation and have raised our target price to SEK150 (145) on our outer-year forecasts.

Eivind Sars Veddeng ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Stefan Gauffin

Nothern Lights

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

Patrik Ling

Getinge (Buy, TP: SEK150.00) - A little soft on the margin

Getinge’s Q2 report was mixed. Sales and order intake were better than expected but adj. EBITA margin fell short of expectations. The company announced additional cost-saving initiatives in the Surgical Workflows (SW) operation and said some effect from these actions should be visible in H2. We believe the company is executing on its turnaround, but that 2019 is still a transition year and there will be a bumpy road for some time. We reiterate our BUY recommendation and have raised our target price to SEK150 (145) on our outer-year forecasts.

Jake Strole

Morningstar | Getinge's Second-Quarter Results Mixed, but Profitability Set to Improve Into 2020; Shares Expensive

No-moat Getinge reported results that largely met our expectations, with strong revenue growth overshadowed by margin performance that remained muted. As we update our model, we don't expect to make major changes but could see a slight uptick in our SEK 97 per share fair value estimate. We view shares as somewhat overvalued following the strong performance year to date. The company posted another quarter of above-trend revenue growth, with a top line that grew 4% organically led by the acute care therapies segment. From a regional perspective, growth in the Americas and in Asia-Pacific drove ...

Jake Strole

Getinge's Second-Quarter Results Mixed, but Profitability Set to Improve Into 2020; Shares Expensive

No-moat Getinge reported results that largely met our expectations, with strong revenue growth overshadowed by margin performance that remained muted. As we update our model, we don't expect to make major changes but could see a slight uptick in our SEK 97 per share fair value estimate. We view shares as somewhat overvalued following the strong performance year to date. The company posted another quarter of above-trend revenue growth, with a top line that grew 4% organically led by the acute car...

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Håkon Astrup
  • Jon Berggren
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Stefan Gauffin
  • Tomi Railo

Weak report across the board

Eivind Sars Veddeng ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Simen Mortensen
  • Stefan Gauffin

Nothern Lights

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

With a more favourable environment, GETINGE AB improves to Positive

GETINGE AB (SE), a company active in the Medical Equipment industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date June 14, 2019, the closing price was SEK 145.00 and its potential was estimated at SEK 156.56.

Nurhayati Wan

Getinge

ResearchPool Subscriptions

Get the most out of your insights

Get in touch